JPRN-UMIN000019616CompletedPhase 2
Phase II study of neoadjuvant nab-paclitaxel and trastuzumab for ER negative and HER2 positive breast cancer - Neoadjuvant nab-PTX and trastuzumab for ER negative and HER2 positive breast cancer
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Osaka Medical College
- Enrollment
- 18
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to 70years-old (—)
- Sex
- Female
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. With history of hypersensitivity reaction for important drug in this study 2. With history of invasive breast cancer 3. Bilateral invasive breast cancer 4. Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus 5. Positive for HBs antigen or HCV antibody 6. With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension 7. With severe edema 8. With severe peripheral neuropathy 9. With severe psychiatric disorder 10. Pregnant or nursing women 11. The case that is judged to be unsuitable for this study by physician
Investigators
Similar Trials
Completed
Phase 2
A study of neoadjuvant nab-paclitaxel followed by FEC for luminal B-like (HER2-negative) and triple-negative breast canceruminal B-like (HER2-negative) or triple-negative operable breast cancerJPRN-UMIN000017675Kyushu Breast Cancer Study Group (KBC-SG)94
Not yet recruiting
Phase 2
Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancerbreast cancerJPRN-UMIN000038715Osaka Medical College35
Completed
Not Applicable
A phase II study of nab-paclitaxel for pretreated non-small cell lung canceron-small cell lung cancerJPRN-UMIN000012972Kanagawa Cancer Center30
Completed
Phase 2
Phase II study of nab-paclitaxel for pretreated NSCLCon-small cell lung cancerJPRN-UMIN000014357Kitasato university hospital, division of respiratory medicine20
Recruiting
Phase 2
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22